hcmv pp65 peptide pool (Miltenyi Biotec)
Structured Review
Hcmv Pp65 Peptide Pool, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hcmv+pp65+peptide+pool/pp65/pm38923358-112-25-31
Average 90 stars, based on 1 article reviews
Images
Related Articles
Cell Culture:Article Title: Engineered HCMV-infected APCs enable the identification of new immunodominant HLA-restricted epitopes of anti-HCMV T-cell immunity. Article Snippet: Funding information German Research Foundation, Grant/Award Number: 431451204; German Centre for Infection Research, Grant/Award Numbers: TTU07.838_00, TTU07.838_01, TTU07.815.00 Complications due to HCMV infection or reactivation remain a challenging clinical problem in immunocompromised patients, mainly due to insufficient or absent T-cell functionality.. Knowledge of viral targets is crucial to improve monitoring of high-risk patients and optimise antiviral T-cell therapy.. To expand the epitope spectrum, genetically-engineered dendritic cells (DCs) and fibroblasts were designed to secrete soluble (s)HLA-A*11:01 and infected with an HCMV mutant lacking immune evasion molecules (US2-6 + 11). Concentration Assay:Article Title: Engineered HCMV-infected APCs enable the identification of new immunodominant HLA-restricted epitopes of anti-HCMV T-cell immunity. Article Snippet: Funding information German Research Foundation, Grant/Award Number: 431451204; German Centre for Infection Research, Grant/Award Numbers: TTU07.838_00, TTU07.838_01, TTU07.815.00 Complications due to HCMV infection or reactivation remain a challenging clinical problem in immunocompromised patients, mainly due to insufficient or absent T-cell functionality.. Knowledge of viral targets is crucial to improve monitoring of high-risk patients and optimise antiviral T-cell therapy.. To expand the epitope spectrum, genetically-engineered dendritic cells (DCs) and fibroblasts were designed to secrete soluble (s)HLA-A*11:01 and infected with an HCMV mutant lacking immune evasion molecules (US2-6 + 11). |
